D
19.13
0.20 (1.06%)
| Penutupan Terdahulu | 18.93 |
| Buka | 18.97 |
| Jumlah Dagangan | 1,228,772 |
| Purata Dagangan (3B) | 1,859,684 |
| Modal Pasaran | 2,805,640,960 |
| Harga / Jualan (P/S) | 3.64 |
| Harga / Buku (P/B) | 3.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -2.64 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.59% |
| Nisbah Semasa (MRQ) | 9.56 |
| Aliran Tunai Operasi (OCF TTM) | -365.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -257.54 M |
| Pulangan Atas Aset (ROA TTM) | -22.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Denali Therapeutics Inc. | Menaik | Menurun |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.38 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.86% |
| % Dimiliki oleh Institusi | 94.15% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (BTIG, 67.28%) | Beli |
| Median | 31.00 (62.05%) | |
| Rendah | 26.00 (JP Morgan, 35.91%) | Beli |
| Purata | 29.67 (55.10%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 17.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 05 Dec 2025 | 32.00 (67.28%) | Beli | 19.00 |
| Wedbush | 05 Dec 2025 | 31.00 (62.05%) | Beli | 19.00 |
| JP Morgan | 04 Nov 2025 | 26.00 (35.91%) | Beli | 14.92 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement |
| 04 Dec 2025 | Pengumuman | Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement |
| 06 Nov 2025 | Pengumuman | Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights |
| 06 Nov 2025 | Pengumuman | Denali Therapeutics Announces Board and Executive Leadership Updates |
| 13 Oct 2025 | Pengumuman | Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |